FDA bans unapproved gout treatments

FDA announced plans to ban unapproved gout treatments, favoring Mutual Pharmaceuticals' new version of the decades-old product, Colcrys. Hikma Pharma, which markets old-time colchicine, says its generics revenue growth will still come in at 20 percent. FDA release | Report